UK pharma has concerns about the new NHS 10-year plan

The Association of the British Pharmaceutical Industry (ABPI) has said that the new 10-year plan for the NHS has underplayed the role that innovative medicines can play in driving advances in healthcare.

In particular, the trade group is concerned that there is no commitment to increase the government’s investment in medicines and reverse “decades of disinvestment in innovative medicines,” as well as a “worrying signal about limiting patient and doctor choices around the best treatment for them.”

That includes elements identified in our coverage of the plan’s highlights, including the…